{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T20:10:26Z","timestamp":1729887026082,"version":"3.28.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,25]]},"DOI":"10.7759\/cureus.72388","type":"journal-article","created":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T19:30:46Z","timestamp":1729884646000},"source":"Crossref","is-referenced-by-count":0,"title":["Clinical Characteristics and Management of Drug-Induced Lupus in Patients Receiving Tumor Necrosis Factor Inhibitor Therapy"],"prefix":"10.7759","author":[{"given":"Ali","family":"Kimiaei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyedehtina","family":"Safaei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malik","family":"Kasapoglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fulya","family":"Co\u015fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Drug-induced lupus erythematosus","author":"Solhjoo M","year":"2023","unstructured":"Solhjoo M, Goyal A, Chauhan K. Drug-induced lupus erythematosus. StatPearls Publishing, Treasure Island (FL); 2023."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198806023182209","article-title":"Drug-related lupus","volume":"318","author":"Hess E","year":"1988","unstructured":"Hess E. Drug-related lupus. N Engl J Med. 1988, 318:1460-2. 10.1056\/NEJM198806023182209","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1191\/0961203302lu236cr","article-title":"Drug-induced lupus following treatment with infliximab in rheumatoid arthritis","volume":"11","author":"Favalli EG","year":"2002","unstructured":"Favalli EG, Sinigaglia L, Varenna M, Arnoldi C. Drug-induced lupus following treatment with infliximab in rheumatoid arthritis. Lupus. 2002, 11:753-5. 10.1191\/0961203302lu236cr","journal-title":"Lupus"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/art.21702","article-title":"Infliximab-related lupus and associated valvulitis: a case report and review of the literature","volume":"55","author":"Chadha T","year":"2006","unstructured":"Chadha T, Hernandez JE. Infliximab-related lupus and associated valvulitis: a case report and review of the literature. Arthritis Rheum. 2006, 55:163-6. 10.1002\/art.21702","journal-title":"Arthritis Rheum"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1177\/0961203308100560","article-title":"Etanercept-associated SLE with lupus nephritis","volume":"18","author":"Neradov\u00e1 A","year":"2009","unstructured":"Neradov\u00e1 A, Stam F, van den Berg JG, Bax WA. Etanercept-associated SLE with lupus nephritis. Lupus. 2009, 18:667-8. 10.1177\/0961203308100560","journal-title":"Lupus"},{"key":"ref6","article-title":"Adalimumab-induced lupus erythematosus with central nervous system involvement in a patient with Crohn's disease","volume":"20","author":"Vannucchi V","year":"2011","unstructured":"Vannucchi V, Grazzini M, Pieralli F, Giannotta M, Biagioni C, Nozzoli C. Adalimumab-induced lupus erythematosus with central nervous system involvement in a patient with Crohn's disease. J Gastrointestin Liver Dis. 2011, 20:201-3.","journal-title":"J Gastrointestin Liver Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2008.09.008","article-title":"Autoimmune diseases induced by TNF-targeted therapies","volume":"22","author":"Ramos-Casals M","year":"2008","unstructured":"Ramos-Casals M, Brito-Zer\u00f3n P, Soto MJ, Cuadrado MJ, Khamashta MA. Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol. 2008, 22:847-61. 10.1016\/j.berh.2008.09.008","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.4065\/84.11.979","article-title":"Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic","volume":"84","author":"Wetter DA","year":"2009","unstructured":"Wetter DA, Davis MD. Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic. Mayo Clin Proc. 2009, 84:979-84. 10.4065\/84.11.979","journal-title":"Mayo Clin Proc"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/ar1715","article-title":"Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey","volume":"7","author":"De Bandt M","year":"2005","unstructured":"De Bandt M, Sibilia J, Le Lo\u00ebt X, et al.. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther. 2005, 7:R545-51. 10.1186\/ar1715","journal-title":"Arthritis Res Ther"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2010.07.005","article-title":"Drug-induced lupus: an update","volume":"10","author":"Katz U","year":"2010","unstructured":"Katz U, Zandman-Goddard G. Drug-induced lupus: an update. Autoimmun Rev. 2010, 10:46-50. 10.1016\/j.autrev.2010.07.005","journal-title":"Autoimmun Rev"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200011)43:11<2383::AID-ANR2>3.0.CO;2-D","article-title":"Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials","volume":"43","author":"Charles PJ","year":"2000","unstructured":"Charles PJ, Smeenk RJ, De Jong J, Feldmann M, Maini RN. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum. 2000, 43:11-2383. 10.1002\/1529-0131(200011)43:11&lt;2383::AID-ANR2&gt;3.0.CO;2-D","journal-title":"Arthritis Rheum"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.043166","article-title":"Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis","volume":"65","author":"Schiff MH","year":"2006","unstructured":"Schiff MH, Burmester GR, Kent JD, Pangan AL, Kupper H, Fitzpatrick SB, Donovan C. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis. 2006, 65:889-94. 10.1136\/ard.2005.043166","journal-title":"Ann Rheum Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1177\/247553031218a00305","article-title":"Etanercept-induced lupus panniculitis with continued improvement after treatment with adalimumab for psoriatic arthritis","volume":"18","author":"Chen TK","year":"2012","unstructured":"Chen TK, Haddican MM, Phelps RG, Spiera H. Etanercept-induced lupus panniculitis with continued improvement after treatment with adalimumab for psoriatic arthritis. Psoriasis Forum. 2012, 18:142-6. 10.1177\/247553031218a00305","journal-title":"Psoriasis Forum"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kei220","article-title":"Drug-induced systemic lupus erythematosus in ankylosing spondylitis associated with infliximab","volume":"45","author":"P\u00e9rez-Garc\u00eda C","year":"2006","unstructured":"P\u00e9rez-Garc\u00eda C, Maymo J, Lisbona P\u00e9rez MP, Almirall Bernab\u00e9 M, Carbonell Abell\u00f3 J. Drug-induced systemic lupus erythematosus in ankylosing spondylitis associated with infliximab. Rheumatology (Oxford). 2006, 45:114-6. 10.1093\/rheumatology\/kei220","journal-title":"Rheumatology (Oxford)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-013-2361-9","article-title":"A case of infliximab-induced lupus in a patient with ankylosing spondylitis: is it safe switch to another anti-TNF-\u03b1 agent?","volume":"32","author":"Santiago T","year":"2013","unstructured":"Santiago T, Santiago MG, Rovisco J, Duarte C, Malcata A, da Silva JA. A case of infliximab-induced lupus in a patient with ankylosing spondylitis: is it safe switch to another anti-TNF-\u03b1 agent?. Clin Rheumatol. 2013, 32:1819-22. 10.1007\/s10067-013-2361-9","journal-title":"Clin Rheumatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/311003-clinical-characteristics-and-management-of-drug-induced-lupus-in-patients-receiving-tumor-necrosis-factor-inhibitor-therapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T19:30:47Z","timestamp":1729884647000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/311003-clinical-characteristics-and-management-of-drug-induced-lupus-in-patients-receiving-tumor-necrosis-factor-inhibitor-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,25]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.72388","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,25]]}}}